Lifesaving, cost-saving: Innovative simplified regimens for drug-resistant tuberculosis.

Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: Aastha Gupta is a consultant to the Global Alliance for TB Drug Development (TB Alliance), a non-profit organization dedicated to the discovery and development of improved TB therapeutics. TB Alliance is funded by governments and foundations and developed pretomanid/BPaL. Sandeep Juneja is an employee of the Global Alliance for TB Drug Development (TB Alliance), a non-profit organization dedicated to the discovery and development of improved TB therapeutics. TB Alliance is funded by governments and foundations and developed pretomanid/BPaL.